Search company, investor...

Predict your next investment

Asset/Investment Management

Investments

3

Portfolio Exits

1

About Lightswitch Capital

Lightswitch Capital is an investment firm.

Headquarters Location

New York, New York,

United States

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Latest Lightswitch Capital News

Precision psychiatry pioneer Alto Neuroscience raises $35M to advance digital biomarker-to-treatment platform

Nov 7, 2022

Precision psychiatry pioneer Alto Neuroscience raises $35M to advance digital biomarker-to-treatment platform November 7, 2022 Alto Neu­ro­science, a Los Altos, CA-based neu­ro-tech com­pa­ny which spe­cial­izes in pre­ci­sion psy­chi­a­try, rais­es $35M Series B Financ­ing … The com­pa­ny intends to use the funds to advance lead can­di­dates into Phase 2b stud­ies in major depres­sive dis­or­der … Pro­ceeds from the financ­ing will also be used to progress the company’s arti­fi­cial intel­li­gence-enabled brain bio­mark­er plat­form and launch new clin­i­cal tri­als in areas of high unmet med­ical need. Alto will report Phase 2a data in ear­ly 2023 and fur­ther antic­i­pates Phase 2b data read­outs by ear­ly 2024. Led by Amit Etkin, M.D., Ph.D., founder and chief exec­u­tive offi­cer, Alto Neu­ro­science pro­vides a pre­ci­sion psy­chi­a­try by devel­op­ing tar­get­ed med­i­cines to help patients get bet­ter. Dif­fer­ences in indi­vid­u­als’ biol­o­gy impact how they respond to treat­ment. Its Pre­ci­sion Psy­chi­a­try Plat­form mea­sures brain bio­mark­ers by ana­lyz­ing EEG activ­i­ty, behav­ioral task per­for­mance, wear­able data, genet­ics, and oth­er fac­tors to match each patient with the right Alto drug. The company’s clin­i­cal-stage pipeline includes nov­el drug can­di­dates in depres­sion, PTSD, and oth­er men­tal health con­di­tions, result­ing in the broad­est and most-advanced pre­ci­sion psy­chi­a­try effort. The Announcement: Alto Neu­ro­science today announced the clos­ing of a $35 mil­lion Series B financ­ing led by Lightswitch Cap­i­tal and part­ners of Alkeon Cap­i­tal, with par­tic­i­pa­tion from oth­er new investors includ­ing Sobra­to Cap­i­tal, Novar­tis Phar­ma AG, Val­or Equi­ty Part­ners, Kori­fy Cap­i­tal, Vine Ven­tures, and Gain­gels. The financ­ing also includ­ed par­tic­i­pa­tion from exist­ing investors Ape­iron Group, WhatIf Ven­tures, Wind­ham Ven­ture Part­ners, and oth­ers. This round brings Alto’s total fund­ing to $75 mil­lion to date … In con­junc­tion with the Series B financ­ing, chief exec­u­tive offi­cer of Lightswitch Cap­i­tal, Christo­pher Cox, and man­ag­ing direc­tor of Alkeon Cap­i­tal, Jeff Chen, Ph.D., have joined the Alto Board of Direc­tors. Addi­tion­al­ly, Bob Baloh, M.D., Ph.D., glob­al head of neu­ro­science at the Novar­tis Insti­tutes for Bio­Med­ical Research (NIBR), will join as a board observer. News in Context:

Lightswitch Capital Investments

3 Investments

Lightswitch Capital has made 3 investments. Their latest investment was in Alto Neuroscience as part of their Series C on November 21, 2023.

CBI Logo

Lightswitch Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/21/2023

Series C

Alto Neuroscience

$45M

No

7

10/25/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

5/16/2022

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/21/2023

10/25/2022

5/16/2022

Round

Series C

Series B

Series C

Company

Alto Neuroscience

Subscribe to see more

Subscribe to see more

Amount

$45M

$99M

$99M

New?

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

7

10

10

Lightswitch Capital Portfolio Exits

1 Portfolio Exit

Lightswitch Capital has 1 portfolio exit. Their latest portfolio exit was Alto Neuroscience on February 02, 2024.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/2/2024

IPO

$99M

Public

2

Date

2/2/2024

Exit

IPO

Companies

Valuation

$99M

Acquirer

Public

Sources

2

Lightswitch Capital Team

1 Team Member

Lightswitch Capital has 1 team member, including current Chief Executive Officer, Christopher Nixon Cox.

Name

Work History

Title

Status

Christopher Nixon Cox

Chief Executive Officer

Current

Name

Christopher Nixon Cox

Work History

Title

Chief Executive Officer

Status

Current

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.